Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2026-02-24 @ 7:45 PM
Study NCT ID:
NCT03132467
Status:
COMPLETED
Last Update Posted:
2024-06-05
First Post:
2017-04-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-13
Start Date Type:
ACTUAL
Primary Completion Date:
2019-01-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-05-20
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-25
First Submit QC Date:
None
Study First Post Date:
2017-04-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-12-28
Results First Submit QC Date:
None
Results First Post Date:
2022-02-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-21
Last Update Post Date:
2024-06-05
Last Update Post Date Type:
ACTUAL